Literature DB >> 11347679

Quinolone-resistance mechanisms and in vitro susceptibility patterns among European isolates of Streptococcus mitis, Streptococcus sanguis, and Streptococcus pneumoniae.

F J Schmitz1, A Fisher, M Boos, S Mayer, D Milatovic, A C Fluit.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11347679     DOI： 10.1007/pl00011257

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


× No keyword cloud information.
  6 in total

1.  New species genetic approach to identify strains of mitis group streptococci that are donors of rifampin resistance to Streptococcus pneumoniae.

Authors:  María-José Ferrándiz; Carmen Ardanuy; Josefina Liñares; Luz Balsalobre; María Teresa García; Adela G de la Campa
Journal:  Antimicrob Agents Chemother       Date:  2010-11-01       Impact factor: 5.191

2.  Emergence of quinolone resistance among viridans group streptococci isolated from the oropharynx of neutropenic peripheral blood stem cell transplant patients receiving quinolone antimicrobial prophylaxis.

Authors:  R M Prabhu; K E Piper; M R Litzow; J M Steckelberg; R Patel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-12       Impact factor: 3.267

3.  Risk factors associated with colonization by pneumococci with reduced susceptibility to fluoroquinolones in adult outpatients.

Authors:  M Raquel Marín Jiménez; Juan Luis Muñoz Bellido; José Angel García Rodríguez
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

4.  Meropenem prevents levofloxacin-induced resistance in penicillin-resistant pneumococci and acts synergistically with levofloxacin in experimental meningitis.

Authors:  P Cottagnoud; M Cottagnoud; F Acosta; L Flatz; F Kühn; A Stucki; J Entenza
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-10-14       Impact factor: 3.267

5.  Fitness of Streptococcus pneumoniae fluoroquinolone-resistant strains with topoisomerase IV recombinant genes.

Authors:  Luz Balsalobre; Adela G de la Campa
Journal:  Antimicrob Agents Chemother       Date:  2007-12-26       Impact factor: 5.191

Review 6.  Moxifloxacin: a review of its use in the management of bacterial infections.

Authors:  Gillian M Keating; Lesley J Scott
Journal:  Drugs       Date:  2004       Impact factor: 9.546
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.